Drug Trial Radar · NCT03289962
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Last checked: Nov 19, 2026Latest source record: Jun 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
273
Actual
Start
Dec 21, 2017
Primary completion
Jul 1, 2025
Study completion Jul 1, 2025
Sponsor
- Lead sponsor
- Genentech, Inc.Roche (Genentech) (RHHBY)
- Sponsor type
- Industry
- Collaborators
- BioNTech SE
- First posted
- Sep 21, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1a/1b, open-label, multicenter, global, dose-escalation study designed to evaluate the safety, tolerability, immune response, and pharmacokinetics of autogene cevumeran (RO7198457) as a single agent and in combination with atezolizumab (MPDL3280A, an engineered anti-programmed death-ligand 1 \[anti-PD-L1\] antibody).
Conditions
- Melanoma
- Non-Small Cell Lung Cancer
- Bladder Cancer
- Colorectal Cancer
- Triple Negative Breast Cancer
- Renal Cancer
- Head and Neck Cancer
- Other Solid Cancers
Interventions
Autogene cevumeranDrug
Autogene cevumeran will be administered by intravenous (IV) infusion, in 21-day cycles.
AtezolizumabDrug
Atezolizumab will be administered by IV infusion on Day 1 of every 21-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants with Dose-Limiting Toxicities (DLTs)Time frame: Phase 1a: Days 1 to 14 / Phase 1b: Days 1 to 21
- MTD/Recommended Phase 2 Dose (RP2D) of Autogene CevumeranTime frame: Phase 1a: Days 1 to 14 / Phase 1b: Days 1 to 21
- Percentage of Participants with Adverse Events (AEs)Time frame: Baseline up to end of the study (up to approximately 3 years)
- Percentage of Participants with Immune-Mediated Adverse Events (imAEs)Time frame: Baseline up to end of the study (up to approximately 3 years)
- Percentage of Participants by Number of Treatment Cycles ReceivedTime frame: Baseline up to end of the study (up to approximately 3 years)
- Dose Intensity of Autogene CevumeranTime frame: Baseline up to end of the study (up to approximately 3 years)
- Change from Baseline in Targeted Vital SignsTime frame: Baseline up to end of study (up to approximately 3 years)
- Change from Baseline in Targeted Clinical Laboratory Test ResultsTime frame: Baseline up to end of study (up to approximately 3 years)
- Change from Baseline in ECGsTime frame: Baseline up to end of study (up to approximately 3 years)
Locations
33 sites in 8 countries. Site status is shown where the registry gives one.
HonorHealth Research Institute ? Bisgrove
Scottsdale, Arizona
The Los Angeles Clinic
Los Angeles, California
UCSF Comprehensive Cancer Ctr
San Francisco, California
Stanford Cancer Center
Stanford, California
University of Colorado
Aurora, Colorado
Yale University Cancer Center, Smilow Cancer Hospital
New Haven, Connecticut
Massachusetts General Hospital.
Boston, Massachusetts
Dana Farber Can Ins
Boston, Massachusetts
Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley
Las Vegas, Nevada
Columbia University Medical Center
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma
Providence Oncology and Hematology Care Eastside
Portland, Oregon
Sarah Cannon Res Inst
Nashville, Tennessee
Seattle Cancer Care Alliance
Seattle, Washington
UZ Gent
Ghent, Belgium
CHU de Liège (Sart Tilman)
Liège, Belgium
ZAS Sint Augustinus Wilrijk
Wilrijk, Belgium
The Ottawa Hospital Cancer Centre
Ottawa, Ontario, Canada
Princess Margaret Cancer Center
Toronto, Ontario, Canada
Universitätsklinikum Essen
Essen, Germany
Nationales Centrum für Tumorerkrankungen Heidelberg (NCT)
Heidelberg, Germany
Fachklinik für Lungenerkrankungen
Immenhausen, Germany
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz
Mainz, Germany
Antoni van Leeuwenhoek Ziekenhuis
Amsterdam, Netherlands
Universitair Medisch Centrum Utrecht
Utrecht, Netherlands
Vall d?Hebron Institute of Oncology (VHIO), Barcelona
Barcelona, Spain
Clinica Universitaria de Navarra
Pamplona, Navarre, Spain
Karolinska Universitetssjukhuset, Solna
Stockholm, Sweden
Akademiska sjukhuset, Onkologkliniken
Uppsala, Sweden
Barts Health NHS Trust - St Bartholomew's Hospital
London, United Kingdom
Southampton General Hospital
Southampton, United Kingdom
The Royal Marsden Hospital
Sutton, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.